Showing results (591-600 of 652) with videos related to

Sort By:
Pageof 66
American Journal of Ophthalmology|August 15, 1985
Orbital magnetic resonance imagingR A Zimmerman, L T Bilaniuk, M Yanoff, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2024
Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)Jennifer H Foster, Joel M Reid, Charles Minard, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 29, 2013
Risk factors for non-initiation of the human papillomavirus vaccine among adolescent survivors of childhood cancerJames L Klosky, Kathryn M Russell, Kristin E Canavera, et al.
Bone Marrow Transplantation|August 22, 2003
Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritisN M Wulffraat, D Brinkman, A Ferster, et al.
Frontiers in Immunology|October 22, 2019
Silica Exposure Differentially Modulates Autoimmunity in Lupus Strains and Autoantibody Transgenic MiceMary H Foster, Jeffrey R Ord, Emma J Zhao, et al.
Journal of Health Communication|May 5, 2011
The art and science of patient storytelling-harnessing narrative communication for behavioral interventions: the ACCE projectThomas K Houston, Andrea Cherrington, Heather L Coley, et al.
The Journal of Biological Chemistry|July 14, 2009
NDRG4 is required for cell cycle progression and survival in glioblastoma cellsStephen H Schilling, Anita B Hjelmeland, Daniel R Radiloff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)Jennifer H Foster, Stephan D Voss, David C Hall, et al.
Cancers|November 26, 2022
ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In VivoYang Yu, Yanling Zhao, Jongmin Choi, et al.
Pediatric Blood & Cancer|July 31, 2020
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factorsSarah B Whittle, Valeria Smith, Allison Silverstein, et al.
Pageof 66